SFRP2 and hepatocellular carcinoma: To the best of our knowledge, no studies till date have systematically analyzed promoter methylation levels of these important Wnt inhibitors (SFRP2 & DKK1) in HCV infected CH & LC patients (without cancer) and compared these methylation levels with infection free normal liver tissues as well as HCC.